Disease relapse is the most important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with acute myelogenous leukemia (AML) and highrisk myelodysplastic syndrome (MDS). 1 The risk of relapse is a function of several factors such as karyotype, disease status, preparative regimen intensity and the development of graftversus-host disease (GVHD). The optimal therapy for recurrence is yet to be determined with most approaches eliciting dismal results. Chemotherapy and donor lymphocyte infusion (DLI) either alone or in combination, or second transplants have been used with different degrees of success. 2, 3 Most studies describing outcomes after disease relapse in the context of reduced intensity conditioning (RIC) allogeneic transplantation involved heterogeneous groups of patients with small sample sizes. It is unclear to what extent patient selection explains the success or failure of salvage strategies. Here, we describe the outcomes of patients with AML and MDS relapsing after their first allogeneic HSCT (HSCT1) with reduced intensity or non-ablative preparative regimens. All patients were treated at the M D Anderson Cancer Center between June 1995 and December 2003. Preparative regimens consisted of either a nonablative regimen of fludarabine, cytarabine and idarubicin (FAI), or with a reduced intensity regimen of fludarabine in combination with either melphalan (FM) or busulfan (FB). Donors were human leukocyte antigen (HLA)-compatible related or unrelated. Stem cell sources were peripheral blood or bone marrow. Complete remission (CR) before HSCT was defined as a normocellular bone marrow with less than 5% blasts and normal maturation of other marrow elements, absence of peripheral blood blasts and a platelet count greater than 100 Â 10 9 /l. CR after HSCT was defined using the same criteria except for platelet count, with donor cell engraftment.
At HSCT1, 122 patients received RIC due to age older than 55 years, while 86 had comorbidities that prevented the use of fully ablative HSCT. Median age was 56 years (n ¼ 208; range, 22-75). Most patients had poor prognostic factors at the time of the HSCT with only 25% in CR. Fifty-three percent of patients received stem cells form a matched related donor, 38% from a matched unrelated donor and 9% from a mismatched related donor. Peripheral blood and bone marrow were the stem cell sources in 53 and 47% of the patients, respectively. Nineteen patients died early and 189 patients were evaluable for response to allogeneic HSCT on day 30 ( Figure 1 ). Sixteen patients did not achieve remission, that is no response (NR) and 173 patients were in CR on day 30. Sixty-three of 173 patients, who were in CR post-transplant, subsequently had disease progression (36%). The median interval between HSCT and relapse was 3.7 months (range 0.3-79 months). As expected, active disease at allogeneic HSCT was the major predictor of disease progression (hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.3-4.3). Stem cell source and donor type (unrelated versus related) had no significant effect on risk of disease progression. Chimerism information was available in 93% of evaluable cases (n ¼ 189) on day 30 after transplant. Most were complete donor chimeras (n ¼ 140), while 35 patients had mixed chimerism and one had autologous reconstitution. Mixed chimerism on day 30 was associated with risk of disease progression (HR of 2.9; 95% CI 1.66-5.04; P ¼ o0.01).
Detailed salvage therapy information was available in 56 of 63 patients (89%). Six patients were treated in other institutions and one patient was lost to follow-up. Relapsed patients were studied in two groups. Seventeen patients (30%) received palliative care or had immunosuppressive (IS) withdrawal as the only intervention for their relapse after HSCT. These patients were not considered for other salvage therapy either because of poor performance status, comorbid conditions, donor unavailability or patient preference. Thirty-nine patients that received chemotherapy, DLI and second allogeneic HSCT (HSCT2) with or without withdrawal of IS were analyzed in the salvage therapy group (70%) ( Table 1 ). Demographic and diseaserelated characteristics were similar in the palliative care and salvage therapy subgroups other than the higher frequency of recipients of unrelated donor transplants in the group of patients that did not receive salvage therapy (P ¼ 0.04).
Forty-eight (86%) patients were receiving IS therapy at relapse. Withdrawal of immunosuppression was performed in 45 of these cases without active GVHD. Three patients (6.6%) achieved CR after IS withdrawal. Patients who responded to IS withdrawal had low bulk disease at relapse (less than 10% blasts in the bone marrow without circulating blasts). Thirty-one of 42 patients with NR to IS withdrawal received further treatments. The response rate to withdrawal of IS was therefore very poor, with the caveat that the median time interval between this intervention and initiation of any salvage therapy was 19 days, reflecting rapid disease progression.
Patients with rapidly evolving relapses were generally referred for salvage chemotherapy first, while more indolent relapses were to undergo HSCT2 or DLI if possible. First-line salvage therapy consisted of DLI (n ¼ 8), HSCT2 (n ¼ 7) and chemotherapy (n ¼ 24). CR rates were 44% after HSCT2, 44% after salvage chemotherapy, and zero after DLI alone. Eight of 10 patients who achieved CR after chemotherapy were consolidated with either a second allogeneic HSCT (n ¼ 7) or DLI (n ¼ 1); all eight remained in remission. Two patients who did not receive consolidation relapsed at 12 and 68 days after achieving CR. None of the patients failing first-line therapy was able to achieve Figure 1 Natural history of acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (HSCT). Salvage therapy was more likely to be effective for patients who received the first transplant in complete remission (CR).
Letters to the Editor long-term disease control with second-or third-line therapy including allogeneic HSCT. Overall CR rate to salvage therapy given as first line and beyond was 39% (n ¼ 15). Disease status at the time of HSCT1 was the most important prognostic factor for response after salvage therapy (CR rate of 70% for patients in remission versus 30% for those with active disease, P ¼ 0.04).
HSCT2 was performed in 18 patients, 46% of patients receiving salvage therapy (or 32% of all relapsed patients, in which information was available). Recipients of HSCT2 were more likely to have been in CR at HSCT1 (44 versus 10%, P ¼ 0.01), less likely to have high-risk karyotype at diagnosis (30 versus 70%, P ¼ 0.054), and more likely to have had longer remission duration after first transplant (4.2 versus 2 months, P ¼ 0.002) than patients treated otherwise. In all but one case, the same donor was used for HSCT2. Donors were unrelated (n ¼ 3), one antigen mismatched relatives (n ¼ 3) or matched siblings (n ¼ 12). Preparative regimens for the HSCT2 included FM (n ¼ 7), FB (n ¼ 4), fludarabine and cytarabine (FA) with gemtuzumab ozogamicin (n ¼ 2), MF alone (n ¼ 1), and total body irradiation and cyclophosphamide (n ¼ 1). Three transplants were performed after myelosuppression induced by gemtuzumab ozogamicin (n ¼ 2) or an investigational agent (n ¼ 1); two of these patients achieved a CR. Overall CR rate was 67%. Response rate for patients with active disease at HSCT2 was 45%. Graft failure was documented in three patients.
Grade I-II and III-IV acute GVHD occurred in 45 and 6% of the patients, respectively. All but two patients did not have acute GVHD after HSCT1. Six patients developed chronic GVHD following HSCT2 (limited in two and extensive in four). All but one case of chronic GVHD developed 'de novo'. There were no acute GVHD-related deaths, but three patients died of chronic GVHD while in remission. There was a trend for improved freedom from disease progression in patients with grade II-IV acute GVHD and chronic GVHD, however, the sample size was small for a conclusive analysis.
Four of 15 patients (27%) who achieved a remission with any salvage therapy had disease progression. Seven patients were alive in remission at the time of this analysis, with a median follow-up of 22.6 months (range, 11-68). Causes of death included relapse (n ¼ 6, 39%), chronic GVHD (n ¼ 3, 17%) and regimen-related toxicities (n ¼ 1, 5.5%). Cumulative incidence of non-relapse mortality was 22%.
All long-term survivors received HSCT2 as a part of their salvage therapy. HSCT2 performed as initial salvage or as consolidation therapy, elicited a median survival of 25.3 versus 2.4 months respectively, when compared to all other salvage approaches (P ¼ 0.0001; Figure 2a ). All 21 patients treated without allogeneic transplant died from their disease.
Although the improvement in survival after relapse with second allogeneic HSCT was most impressive in patients in CR at HSCT1 (median survival not reached), there was still a significant benefit in patients with active disease at HSCT1 compared to other salvage therapies (5.9 versus 1.9 months) (Figure 2b ). The disease status at second transplant was not found to affect survival after the second transplant (P ¼ 0.5).
Leukemia relapse after allogeneic transplantation is generally associated with a dismal prognosis with many patients and physicians opting for no further therapy. Many reports addressing the natural history of AML/MDS relapsing after an allogeneic transplant have done so in the context of myeloa- Letters to the Editor blative conditioning. This is the largest analysis of patients with AML/MDS who relapsed after a RIC. The natural history of AML/ MDS relapsing after RIC may be potentially different due to intrinsic differences in patients that are selected for RIC versus fully ablative therapies, as well as tolerance of treatment after a fully ablative versus a RIC. Disease status has been identified as the single most important prognostic factor for survival after allogeneic HSCT for AML/MDS. [4] [5] [6] This analysis also demonstrates that even for patients relapsing after an initial allograft with RIC, the disease status at the time of the initial HSCT also predicts outcome of salvage therapies. We failed to detect a correlation between type of preparative regimen and outcomes of salvage therapy.
We were also unable to confirm a role for DLI alone or with chemotherapy in this unselected population (within the limitations imposed by the relatively small number of observations in some of the treatment groups). Although there have been encouraging results with DLI to treat CML and indolent lymphomas recurring after ablative and RIC allogeneic HSCT, results in AML/MDS are generally more modest. This is likely due to a decreased sensitivity to the graft versus leukemia (GVL) effect. We did not observe any CR with DLI alone. Likewise, immunosuppression withdrawal by itself was largely ineffective and cannot be recommended based on our experience. Chemotherapy was the initial treatment for relapse in 62% of the treated patients, but since a variety of regimens were used, we cannot suggest a specific agent based on this analysis. Chemotherapy-related mortality was 8% and the CR rate 42%. The Seattle group reported a 34% response rate in 44 AML patients relapsing after ablative transplants that were treated with combination chemotherapy. 3 In that study, more than half of the patients were in CR at transplant and median relapse-free survival was 6.5 months. In our study, 70% of the patients treated with chemotherapy as initial salvage had active disease at HSCT1, and median relapse-free survival was 2.5 months. Remissions with chemotherapy alone were not durable and essentially all patients that did not receive consolidation with a second transplant or DLI relapsed. We observed similar response rates with chemotherapy as first line therapy or with a second transplant upfront. Regardless of the sequence, cytoreduction seems to be a key part of a successful salvage approach.
A subset of patients may achieve durable remissions with a second HSCT (2 year actuarial survival of 50%). In general, this group was comprised of patients that underwent HSCT1 in CR and consequently had longer remission duration after initial transplant. Similarly, patients with active disease at HSCT1 with longer CR duration appear to benefit from HSCT2 as demonstrated previously mostly in the context of ablative transplants. 4, [6] [7] Our results suggest that considering dismal outcomes with withdrawal of immunosuppression, DLI and chemotherapy alone, a second allogeneic HSCT should be considered in this setting. Whether salvage chemotherapy should be used earlier to transplant is unclear, and the decision may be dictated by donor availability, presence of GVHD, absence of major infections, disease 'tempo', performance status and duration of remission after the first transplant. For relapses occurring during the first 100 days, we usually recommend salvage chemotherapy, and if a CR is achieved, second transplant. For recurrences occurring subsequently, disease 'tempo' is probably a key factor. It is feasible to proceed directly to a second transplant in pancytopenic patients with a good general medical status. Participation in clinical trials is to be encouraged at all times, given the lack of clearly established guidelines in this setting. We used the same donor, unless a second HLA-identical sibling is readily available. The usefulness of utilizing a second donor, under the assumption of searching for a better GVL effect, is unproved.
Interventions designed to prevent recurrence are to be implemented early, during a stage where most patients are in a state of minimal residual disease. Clinical trials with early interventions for patients at high risk of relapse should be encouraged in AML/MDS, since a significant fraction of the patients will die of disease relapse. These trials may include immunologic interventions such as vaccines or 'educated' T-cell therapy, or pharmacologic approaches such as hypomethylating agents, drugs that may promote tumor immunogenicity and maximize the GVL effect at low doses. The JAK2 V617F mutation is found in the vast majority of patients with polycythemia vera (PV) and this change is proposed to be one of diagnostic tools for PV, 1 while the presence of idiopathic erythrocytosis with other JAK2 mutations is currently demonstrated. 2 PV patients with JAK2 V617F have significantly higher leukocytes and platelets, and a higher frequency of palpable splenomegaly at the time of diagnosis. 3, 4 It is reported that thrombotic events in PV patients are not linked to JAK2 V617F mutational status. 3, 5 Moreover, although thrombosis is a major complication in PV patients, 1 no hematologic parameters during followup could be shown to predict thrombosis. 1, 6 We, therefore, assessed the association between thrombosis and hematologic indicators both at diagnosis and during the courses of PV patients, in combination with JAK2 V617F mutational status, to find out the possible risk factor for thrombosis in PV patients.
We analyzed 33 patients with PV (followed for at least 1 year) based on the PV Study Group criteria: seven patients were non-WHO PV and the remaining 26 met the World Health Organization (WHO) criteria. The JAK2 V617F mutation was determined by using the sequence-specific primer-single molecule fluorescence detection assay. 3 As reported previously, PV patients with JAK2 V617F (n ¼ 24) had a significantly higher leukocyte count (Po0.0001) and platelet (Po0.0001) at the time of PV diagnosis, while there was no significant difference in the frequency of thrombotic episodes (1/9 versus 5/24: P ¼ 0.5190) (Supplementary Table 1) . 3 None of the 33 PV patients showed MPL 515 mutation (data not shown). The frequency of thrombosis (3/17 versus 2/7: P ¼ 0.5492) and initial hematologic parameters did not show any significant difference between PV patients with heterozygous and homozygous JAK2 V617F . We next compared the maximal levels of hematologic data during followup in PV patients with or without thrombotic episodes. Notably, PV patients with thrombosis (n ¼ 6) had a significantly higher platelet count during their courses (9877460 Â 10 9 /l versus 6047335 Â 10 9 /l: P ¼ 0.0349), while the initial platelet count between these two groups did not show any significant difference (P ¼ 0.3722) ( Table 1 ). This tendency was also evident in PV patients with JAK2 V617F (P ¼ 0.0612). The frequency of thrombosis was not influenced by the anti-thrombotic treatment (P ¼ 0.0742 in total PV, and P ¼ 0.2611 in PV with JAK2 V617F ). The presence of JAK2 V617F mutation was related to initial platelet counts in PV patients, 3 but not to thrombotic episodes. In the current study, the increased amount of platelets during follow-up (delta platelets ¼ maximal platelets during follow-upinitial platelets) correlated with thrombotic episodes (P ¼ 0.0318), but did not show any significant association with the JAK2 V617F mutational status ( Table 1) . Five of six patients with thrombosis had additive elevated platelet counts of 4250 Â 10 9 / l during the follow-up period from the base-line platelets. This aspect requires further confirmation using large cohort studies, since we encountered only 6/33 PV patients with thrombosis. Our data indicate that uncontrolled thrombocytosis, despite administration of cytoreductive chemotherapy, may be a risk factor for developing thrombosis.
Management for PV patients focused on the reduction of hematocrit level for less than 45% in men and less than 42% in women by either phlebotomy or administration of hydroxyurea. 1 Although aspirin administration is recommended for PV patients, 1 aspirin therapy might be insufficient to prevent thrombosis in some PV patients with prominent thrombocytosis. Moreover, the timing of thrombosis in PV patients did not coincide with the maximal platelet count during followup (data not shown), in agreement with other reports. 6 Finazzi et al. reported that the risk of thrombosis in JAK2
V617F
-positive PV was 3.63-fold that of those with wild-type JAK2 essential thrombocythemia (ET), while Tefferi et al. 5 found no association between JAK2 V617F mutational status and bleeding or thrombotic history. Vannucchi et al.
8 also confirmed the lack of any difference in the frequency of thrombosis between PV patients with heterozygous and homozygous JAK2 V617F . Some JAK2 V617F -positive PV cases show hematologic transformation among CMPD and tend to exhibit thrombosis or myelofibrosis during their courses; 1, 3, 4 Di Nisio et al. 6 did not find any association between platelet count during follow-up and thrombotic events
